Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T21:35:40.756Z.
Calculation as of: 2026-10-06T21:35:40.756Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a397cd850420951a0c9724a6b76f21fabdb26d17d869f1b33831b183cdf643d3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Market Cap
$1.88M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.84M
EV/Sales Ratio
1.10x
TTM Avg
1.12x
3Y Avg
0.78x
5Y Avg
17.94x
Market Cap
$1.81M
EV/Sales Ratio
563.02x
TTM Avg
926.43x
3Y Avg
825.26x
5Y Avg
621.23x
Market Cap
$2.14M
EV/Sales Ratio
0.60x
TTM Avg
1.34x
3Y Avg
1.17x
5Y Avg
1.11x
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Autonomix Medical, Inc. (AMIX) | $1.88M | N/A | N/A | N/A | N/A |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | 1.10x | 1.12x | 0.78x | 17.94x |
| Beyond Air, Inc. (XAIR)vs › | $1.84M | N/A | 3.53x | 139.43x | 239.41x |
| Profusa, Inc. Common Stock (PFSA)vs › | $1.83M | N/A | N/A | N/A | N/A |
| Alaunos Therapeutics, Inc. (TCRT)vs › | $1.81M | 563.02x | 926.43x | 825.26x | 621.23x |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | 1.51x | 4.91x | 63.51x |
| Silo Pharma, Inc. (SILO)vs › | $1.64M | N/A | 14.01x | 35.72x | 58.79x |
| Vivos Therapeutics, Inc. (VVOS)vs › | $2.14M | 0.60x | 1.34x | 1.17x | 1.11x |
| Lakewood-Amedex Biotherapeutics, Inc. (LABT)vs › | $1.52M | N/A | N/A | N/A | N/A |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
